- Eyenovia (NASDAQ:EYEN) is trading ~5% higher premarket after it announced positive results from a research study that showed Optejet delivery technology decreased inflammation from preserved glaucoma solutions compared to drops.
- The study evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment was administered via Optejet versus latanoprost+BAK administered via standard eye drops.
Eyenovia rises on positive data from Optejet delivery technology trial
Recommended For You
About EYEN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EYEN | - | - |
Eyenovia, Inc. |